| |
Representative
publications |
(in international journals
in English)
1. Bartalena L, Tata JR, Robbins J: Characterization of nascent and
secreted thyroxine-binding globulin in cultured human hepatoma (Hep
G2) cells. J Biol Chem 259: 13605, 1984.
2. Bartalena L, Robbins J: Effect of tunicamycin and monensin on secretion
of thyroxine-binding globulin by cultured human hepatoma (Hep G2)
cells. J Biol Chem 259: 13610, 1984.
3. Bartalena L, Grimaldi S, Fleischmann K, Robbins J: Biosynthesis
of a novel thyroxine-binding protein (27 K protein) in human hepatoma
(Hep G2) cells. Endocrinology 118: 2370, 1986.
4. Bartalena L, Martino E, Antonelli A, Pacchiarotti A, Robbins J,
Pinchera A: Effect of the antileukemic agent L-asparaginase on thyroxine-binding
globulin and albumin synthesis in cultured human hepatoma (Hep G2)
cells. Endocrinology 119: 1185, 1986.
5. Bartalena L, Martino E, Pacchiarotti A, Grasso L, Aghini-Lombardi
F, Buratti L, Bambini G, Breccia M, Pinchera A: Factors affecting
suppression of endogenous thyrotropin secretion by thyroxine treatment:
retrospective analysis in athyreotic and goitrous patients. J Clin
Endocrinol Metab 64: 849, 1987.
6. Bartalena L, Robbins J, Pacchiarotti A, Martino E, Pinchera A:
Further studies on the role of glycosylation in thyroxine-binding
globulin (TBG) secretion by human hepatoma (Hep G2) cells. Endocrinology
121: 1497, 1987.
7. Bartalena L, Martino E, Falcone M, Buratti L, Grasso L, Mammoli
C, Pacchiarotti A, Aghini-Lombardi F, Balzano S, Pinchera A: Evaluation
of the nocturnal serum thyrotropin (TSH) surge, as assessed by TSH
ultrasensitive assay, in patients receiving long term L-thyroxine
suppression and in patients with various thyroid disorders. J Clin
Endocrinol Metab 65: 1265, 1987.
8. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera
A: Use of corticosteroids to prevent progression of Graves' ophthalmopathy
after radioiodine therapy for hyperthyroidism. N Engl J Med 321: 1349,
1989.
9. Bartalena L: Recent achievements in studies on thyroxine-binding
proteins. Endocr Rev 11: 47, 1990.
10. Bartalena L, Martino E, Petrini L, Velluzzi F, Loviselli A, Grasso
L, Mammoli C, Pinchera A: The nocturnal serum thyrotropin surge is
abolished in patients with adrenocorticotropin (ACTH)-dependent or
ACTH-independent Cushing's syndrome. J Clin Endocrinol Metab 72: 1195,
1991.
11. Bartalena L, Farsetti A, Flink IL, Robbins J: Effects of interleukin-6
on the expression of thyroid hormone-binding protein genes in cultured
human hepatoblastoma-derived (Hep G2) cells. Mol Endocrinol 6: 935,
1992.
12. Bartalena L, Cossu E, Grasso L, Velluzzi F, Loviselli A, Cirillo
R, Martino E: Relationship between nocturnal serum thyrotropin peak
and metabolic control in diabetic patients. J. Clin. Endocrinol. Metab.
76: 983, 1993.
13. Bartalena L, Hammond GL, Farsetti A, Flink IL, Robbins J: Interleukin-6
inhibits corticosteroid-binding globulin synthesis by human hepatoblastoma-derived
(Hep G2) cells. Endocrinology 133: 291, 1993.
14. Bartalena L, Grasso L, Brogioni S, Aghini-Lombardi F, Braverman
LE, Martino E: Serum interleukin-6 in amiodarone-induced thyrotoxicosis.
J. Clin. Endocrinol. Metab. 78: 423, 1994.
15. Bartalena L, Brogioni S, Grasso L, Rago T, Vitti P, Pinchera A,
Martino E: Interleukin-6: a marker of thyroid-destructive processes?.
J. Clin. Endocrinol. Metab. 79: 1414, 1994.
16. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino
E: Treatment of amiodarone-induced thyrotoxicosis: results of a prospective
study. J. Clin. Endocrinol. Metab. 81: 2930, 1996.
17. Bartalena L, Marcocci C, Pinchera A: Treating severe Graves' ophthalmopathy.
Bailliere's Clin Endocrinol Metab. 11: 521, 1997.
18. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto
E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino
E, Pinchera A: Relation between therapy for hyperthyroidism and the
course of Graves' ophthalmopathy.N. Engl. J. Med. 338: 73, 1998.
19. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei
MP, Nardi M, Martino E, Pinchera A: Cigarette smoking and treatment
outcomes in Graves' ophthalmopathy. Ann. Intern Med. 129: 632, 1998.
20. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy:
reality and perspectives. Endocr Rev 21: 168, 2000.
21. Bartalena L, Marcocci C, Pinchera A. Graves’ ophthalmopathy:
a preventable disease? Eur J Endocrinol 146: 457, 2002.
22. Bartalena L, Marcocci C, Gorman CA, Wiersinga WM, Pinchera A.
Orbital radiotherapy for Graves’ ophthalmopathy: Useful or useless?
Safe or dangerous? J Endocrinol Invest 26: 5, 2003.
23. Bartalena L, Tanda ML, Piantanida E, Lai A. Oxidative stress and
Graves’ ophthalmopathy: in vitro studies and therapeutic implications.
Biofactors 19: 155, 2003.
24. Bartalena L, Marcocci C, Pinchera A. Orbital radiotherapy for
Graves’ ophthalmopathy. J Clin Endocrinol Metab 89: 13, 2004.
25. Bartalena L, Wiersinga WM, Tanda ML, Bogazzi F, Piantanida E,
Lai A, Martino E: Diagnosis and management of amiodarone-induced thyrotoxicosis
in Europe: results of an international survey among members of the
European Thyroid Association. Clin Endocrinol 61: 494, 2004.
26. Bartalena L, Marcocci C, Pinchera A: Somatostatin analogs for
Graves’ ophthalmopathy: do they bounce off like a rubber bullet?
J Clin Endocrinol Metab 89: 5908, 2004.
27. Bartalena L, Bogazzi F, Pinchera A, Martino E: Treatment with
thionamides before radioiodine therapy for hyperthyroidism: yes or
no? J Clin Endocrinol Metab 90: 1256, 2005.
28. Bartalena L, Tanda ML, Bogazzi F, Piantanida E, Lai A, Martino
E: An update on the pharmacological management of hyperthyroidism
due to Graves’ disease. Exp Opin Pharmacother 6: 851, 2005.
29. Bartalena L, Tanda ML, Piantanida E, Lai A: Glucocorticoids and
outcome of radioiodine therapy for Graves’ hyperthyroidism.
Eur J Endocrinol 153: 13, 2005.
30. Bartalena L: Glucocorticoids for Graves’ ophthalmopathy:
how and when. J Clin Endocrinol Metab 90: 5497, 2005. |